This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
MiMedx Group Inc.
Drug Names(s): human amniotic membrane allograft
EpiFix is a human amniotic membrane allograft and is composed of multiple layers including a single layer of epithelial cells, a basement membrane and an avascular connective tissue matrix. EpiFix provides a biologically active matrix and growth factors for cellular ingrowth, and it reduces inflammation and reduces scar tissue formation for enhanced healing.
EpiFix is regulated by the FDA under 21 CFR Part 1271 Human Cells, Tissues and Cellular and Tissue-based Products (HCT/Ps).
Additional information available to subscribers only: